CLINICAL_TRIALS
trial_result
· 2017-06-20
Clinical Trial Update: [11C]Carfentanil PET Study of GSK1521498 [Phase 1]
Summary
Phase 1 trial update of the mu-opioid receptor antagonist GSK1521498 in obesity using [11C]carfentanil PET. The study status is completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: GlaxoSmithKline | Conditions: Obesity | Phase 1 | Status: COMPLETED